Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low […]
Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. December 19, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology […]
Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option. Aclarion, Inc., (“Aclarion” or the […]
Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the […]
NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain Nociscan to be commercially active across seven participating major academic medical centers Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that […]
Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial clinical evaluations with 87% of patients treated at discs identified as painful by Nociscan continuing to show significant clinical improvements […]
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
